<DOC>
	<DOCNO>NCT02165761</DOCNO>
	<brief_summary>To characterize GORE® Hybrid Vascular Graft compare non-heparin bond synthetic vascular graft term prevalence persistence anti-platelet factor 4 / heparin antibody ( anti-PF4 / H antibody ) .</brief_summary>
	<brief_title>Evaluation Anti-platelet Factor 4/Heparin Antibodies Hemodialysis Patients</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<mesh_term>Platelet Factor 4</mesh_term>
	<criteria>The patient candidate native fistula . The patient require creation upper arm vascular access graft hemodialysis secondary diagnosis EndStage Renal Disease . The patient hemodialysis ≥1 month . The patient schedule different surgical procedure within 30 day post Index Procedure . The patient know hypercoagulable disorder bleed disorder . The patient previous instance Heparin Induced Thrombocytopenia Type II ( HIT type II ) know sensitivity heparin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Hemodialysis</keyword>
	<keyword>End Stage Renal Disease</keyword>
	<keyword>Vascular Graft</keyword>
</DOC>